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Abstract: Nitric oxide (NO) is an essential signaling molecule within biological systems and is believed
to be involved in numerous diseases. As a result of NO’s high reaction rate, the detection of the
concentration of NO, let alone the presence or absence of the molecule, is extremely difficult. Researchers
have developed multiple assays and probes in an attempt to quantify NO within biological solutions,
each of which has advantages and disadvantages. This review highlights many of the current NO
sensors, from those that are commercially available to the newest sensors being optimized in research
labs, to assist in the understanding and utilization of NO sensors in biological fields.
Keywords: nitric oxide; sensors; biomedical engineering
1. Introduction
Nitric oxide (NO) is a molecule that has recently attracted heightened interest due to its vast role
in human health and biology. Nearly 35 years ago NO was identified as an endothelial relaxing factor,
a discovery which garnered Robert F. Furchgott, Ferid Murad, and Louis J. Ignarro a Nobel prize for
medicine or physiology in 1998 [1]. However, in the past 20 years NO has also been shown to play
a significant role in a multitude of physiological systems including the central nervous system (CNS),
the cardiovascular system, the gastrointestinal tract, the immune system, and the renal system [2–6].
Within the CNS, NO acts as a neurotransmitter, and it has been shown to regulate feelings of pain,
appetite, the sleep-wake cycle, thermoregulation, synaptic plasticity, and neural secretion [2,7–13].
NO may also act as a neuroprotective or degradative agent, depending upon its concentration within
the surrounding tissue [2,14–16]. Aside from its aforementioned role in vasodilation, NO also plays
a significant role in the modulation of platelet aggregation, smooth muscle cell proliferation, and LDL
(low density lipoprotein) cholesterol oxidation within the cardiovascular system [1,17–19].
Within the gastrointestinal tract, NO protects the stomach epithelium by stimulating mucosal
and bicarbonate secretions [4,20,21]. NO may also confer protection to the mucosal layer by inhibiting
gastric acid secretion and leukocyte adhesion to the epithelium [4,5,22,23].
The role of NO within the immune system is immense, and while much is known about some
specific roles of NO, its behavior outside of norms is still largely uncharted. A well-known role of
NO within the immune system is its antitumor and microbial effects. Macrophage-derived NO can
cause tumor cells senescence or death [5,24]. Cytotoxic lymphocytes can also induce NO expression
within tumor cells via interferon-γ and tumor necrosis factor (TNF), again resulting in senescence or
death [5,25]. Paradoxically, it is not uncommon for tumor cells to constitutively express NO, aiding in
tumor growth by increasing neovascularization and upregulating the production of DNA dependent
protein kinases (DNA-PKcs), which are required for DNA repair [5,26,27]. In addition to antitumor
effects, NO has been shown to display significant antimicrobial properties and its expression by
immune and epithelial cells has been shown to decrease replication and kill infectious agents [5,28].
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In the renal system, NO is principally responsible for regulating blood pressure and flow to the
kidneys [29]. NO has also been implicated in natriuresis and diuresis due to its ability to inhibit sodium
transport within the nephron [6].
As a result of NO’s widespread impact on cell and tissue health, there are also numerous
inflammatory diseases linked to the altered expression of NO [30–34]. There are both disease-promoting
and disease-inhibiting reactions in the tumor microenvironment that are associated with changes in NO
concentration, which has resulted in confusion about the role of NO during disease progression [35–37].
An example of this can be seen with melanoma, a type of skin cancer, in which different researchers
have shown that nitric oxide synthase (NOS) and NO are both directly and inversely correlated to
apoptosis, metastasis, and disease progression [38–41].
Unsurprisingly, NO’s diverse effect on numerous bodily functions has led some working in the field
of human health to utilize NO in the development of new medical techniques and practices. Some more
notable accomplishments utilizing NO include a reversal of hypoxic pulmonary vasoconstriction using
inhaled NO, the development of an antimicrobial sol-gel for coating biomaterials used in implants,
and an electrochemical oxygen probe which uses NO as an anticlotting agent [42–44].
NO’s reactivity, one of the traits that makes it such an effective signaling molecule, also makes it
extremely difficult to quantify [45,46]. The half-life of NO is largely dependent on the microenvironment
into which it is released. Environments low in available bioreactive molecules will increase the half-life of
NO substantially. As a result, great discrepancies exist in the accepted biological half-life of NO [47–49].
However, the generally accepted half-life for NO in blood is 0.05–1 millisecond [34,50–54], breaking
down into multiple stable and non-stable molecules (Figure 1) [50,55–57]. When NO’s reactivity rate is
combined with its synthesis through NOS, a complicated biological system is created which cannot easily
be understood.
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WI, USA) determines nitrite concentration, since it is a stable byproduct of NO, and can be utilized 
to calculate the concentration of NO that was present in a sample before degradation occurred. The 
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Before the importance of NO in biological systems can be fully u derstood, s nsor to detect
and quantify NO needs to be developed. There are multiple sensors currently on the market or being
developed in research labs, all of which have their own advantages and disadvantages. This review
will cover some of the main NO sensors currently in use and in development in an attempt to elucidate
the areas of sensor development success and the areas in which further research is still needed.
2. Upstream and Downstream Measurements
Because of NO’s high reactivity rate, examining upstream or downstream indicators of NO is
a popular method to estimate NO concentration within samples. The Griess assay (Promega, Madison,
WI, USA) determines nitrite c centration, since it is a st ble byproduct of NO, and can b utilized to
calculat the concent ation of NO t at was present in a sample before deg dation occurred. The Griess
test was originally published by Peter Griess in 1879 and many alterations have been made to create the
current commercially available assay, although it still relies upon the diazotization reaction that Griess
originally described [58]. The Griess test is relatively simple, requiring the addition of sulfanilamide
in phosphoric acid and then N-1-napthylethylenediamine dihydrochloride to the samples of interest,
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as depicted in Figure 2 [59]. The solution will change color due to the azo compound and absorbance
measurements can be compared to a standard to determine the concentration of nitrite in the samples.
The Griess method uses standard biology- and chemistry-based methods in combination with
instruments that are commercially available. Unfortunately, these assays only make an approximation
of the NO level within a solution, a problem that has led researchers to find contradictory results when
comparing the predicted NO levels through different analysis methods [60].
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Figure 2. The Griess assay that is currently commercially available from Promega has undergone
many changes and optimizations, but the diazotization reaction published by Griess is still the central
component of the Griess test [58,59].
An alternate method of predicting NO concentr tion within a system is performed by examining
upstream components suc as NOS activity. First characterized in 1989 [61], NOS is found in three
different forms within the body which are named after the location the enzyme was originally
discovered: neuronal, inducible, and endothelial NOS (nNOS, iNOS, and eNOS) [62–64]. All three
isoforms of NOS utilize L-arginine as a substrate, with reduced nicotinamide-adenine-dinucleotide
phosphate (NADPH) and oxygen as co-substrates to produce NO and citrulline as a byproduct,
as shown in Figure 3 [61,65,66]. Detection of the concentration of [3H]citrulline created in the presence
of [3H]arginine through liquid scintillation spectroscopy is a straightforward assay used to measure
NO synth sis [67]. Bredt a d Snyder state that their measurements were performed through a “simple,
sensitive, and specific ass y” [67] a they received results that were similar through repea ed trials,
supporting their claims. Unfortunately, the use of radiolabeled molecules adds a level of complication
that many labs find undesirable. Advancement in the field has led to colorimetric and fluorometric
assays for citrulline from labeled L-arginine, and many kits are available commercially (e.g., Abcam
or Cayman Chemical). However, these assays cannot reliably be used for in vivo systems since the
body’s natural arginine supplies would interfere with the readings. Additionally, these assays suffer
from an inability to produce localized measurements. While the assays can inform a researcher about
the NO that is being produced in an entire system, they are not able to identify the specific areas of NO
production and use throughout a cell or throughout a system of multiple cells.
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S-nitrosothiol (RSNO) is another upstream compound that is utilized to calculate NO concentration,
since it is believed that RSNOs can act as reservoirs or carriers of NO within biological systems without
altering NO’s activity [52,68,69]. The Meyerhoff lab has shown the use of sensors that can reversibly
detect RSNO within blood for a 10-day period, extending the timeframe for NO detection past most of
the other sensor options [70]. The downside of this sensor is that it is detecting an upstream component
of NO and not actual NO concentrations.
3. Electrochemical Detection
Electrochemical sensors are an excellent alternative for researchers that desire a fast and relatively
simple method of determining NO concentration. In 1992, Malinski and Taha demonstrated the ability
of their electrochemical probe, created by covering carbon fibers with polymeric porphyrin followed
by a Nafion coating, to detect NO released from a single cell [71]. The Nafion coating was essential
in the probe development since it is negatively charged and allows NO to pass through the coating
while blocking the passage of nitrite and nitrate, two main downstream components of NO, to the
sensor [71]. Shortly thereafter, Malinski’s lab showed the ability of an electrochemical probe to detect
NO within the vasculature of a living human and demonstrated dose dependent changes with their
system [72].
Since the original development of the electrochemical NO sensor, commercialization has led
to relatively inexpensive, user-friendly instruments consisting of various materials and allowing
for real-time in vitro and in vivo measurements of NO within a solution. One of the commercially
available systems is amiNO (produced by Innovative Instruments, Inc., Tampa, FL, USA), which allows
consumers to choose the size, flexibility, durability, sensitivity, and response time for their system,
has a detection limit of 1 nM of NO, and can differentiate between 10 nM and 11 nM solutions [73].
Two substantial drawbacks of the electrochemical sensor are that it has not been miniaturized to the
point of providing information about NO concentrations throughout a cell and it is not a sensor that
can monitor NO over long time intervals while a subject is carrying out natural activities, both of
which would be extremely valuable in understanding NO’s physiological importance.
4. Chemiluminescent Probes
Chemiluminescent probes can be used to detect NO in both liquid and gaseous samples [74–77].
The general scheme for the detection of NO in fluid samples via chemiluminescence is through the
activation of guanylyl cyclase by NO exposure, causing guanosine triphosphate (GTP) to be converted
to guanosine 3′,5′-cyclic monophosphate (cGMP) which results in the release of pyrophosphate,
which can then interact with adenosine triphosphate sulfurylase (ATP-sulfurylase) to form ATP [76,77].
The ATP that is formed through this series of reactions is then able to interact with a luciferin-luciferase
system to emit light at 560 nm [76,77]. An advantage of the chemiluminescent system is that it is able
to detect NO at nM concentrations, since the initial guanylyl cyclase interaction with NO leads to
a 200-fold linear increase [76,77]. Chemiluminescent probes have some disadvantages, including the
inability to detect NO in vivo.
5. Fluorescence Probes
Fluorescence detection methods are an attractive alternative to the previously mentioned sensors
because of their ability to detect both extracellular and intracellular NO as well as their ability
to provide both spatial and temporal information [78]. Various types of fluorescent NO sensors
have been developed, including o-diamino aromatic compounds, luminescent lanthanide complexes,
transition-metal complexes, quantum dots, and carbon nanotube sensors. Each type of fluorescent
sensor has different positive and negative traits; in the following, some of the major fluorescent sensors
are listed with a discussion of their benefits and drawbacks.
A common approach for the generation of NO sensors is through the use of o-diamino aromatic
molecules (as depicted in Figure 4) such as 4,5-diaminofluorescein, commonly known as DAF-2 [79–82].
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Unfortunately, many of the o-diamino sensors have drawbacks, including a false positive signal when
exposed to dehydroascorbic acid (DHA) and ascorbic acid (AA), which often co-localize with NO
synthase, and a sensitivity to pH [83–85]. The Shear research group developed a new NO sensor
in 2010, named NO550, that has a high specificity, does not react to co-localized proteins, and is not
sensitive to pH differences, which is advantageous since various intracellular compartments have
different pH values [86–88]. NO550 shows a red-shifted 1500-fold increase in fluorescence and does not
react to other reactive oxygen and nitrogen species [88]. One drawback of NO550 is that it has limited
aqueous solubility, making it less than ideal for biological studies [88].
An alternate method for NO fluorescence detection is through the use of transition metal-based
complexes, which create a turn-on fluorescent signal. For transition metal-based complexes a fluorophore
is bound to a transition metal and exhibits a very weak signal, but a reaction with NO causes the
displacement of the fluorophore and fluorescence recovery [89,90]. Unfortunately, metal-based complexes
are water-insoluble creating a good NO sensor for organic solvents but not being optimal for many
biological scenarios [91].
Because aqueous solubility is believed to be an important characteristic for biological sensors,
Nagano’s group developed a luminescent lanthanide complex that showed a 50-fold increase in
luminescence (excitation 500 nm and emission 980 nm) after exposure to 50 uM aqueous NO [92].
A benefit of Nagano’s sensor over previously developed Yb3+ complexes lies in the fact that their probe
is functional in aqueous systems, has an excitation wavelength that can be produced via two-photon
technology, and has an emission wavelength in the near-infrared region, where water and blood absorb
minimal light [92].
In 2017, a new fluorescent NO sensor called NCNO, which is based on N-nitrosation reactivity was
developed to avoid non-specific reactions from DHA, AA, and reactive oxygen species [93]. NCNO
covalently binds a two-photon fluorophore to a mono alkyl-substituted p-phenylenediamine, as shown
in Figure 4 [93]. Because the two-photon fluorophore has an emission wavelength greater than 600 nm,
the NCNO probe can be detected deep within tissue and has been shown to detect NO generation in
an ischemia reperfusion injury mouse model [93]. One of the shortcomings of the NCNO detection
system is that N-nitrosation is detected, not total NO concentration, so assumptions and models need
to be used to determine the actual NO concentration in the solution/tissue.
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Figure 4. Comparison of a common o-diamino aromatic probe with the new NCNO probe. (a) shows
a generic o-diamino aromatic probe that is activated by exposure to nitric oxide (NO), dehydroascorbic
acid (DHA), or ascorbic acid (A ); (b) shows the NCNO probe that is also activated by NO, but not by
DHA or AA [93].
Quantum dots (QDs) are a class of nanoparticles that can fluoresce at many different wavelengths
(with narrow emission spectra), do not quickly photobleach, and emit light more than 100 times
stronger than organic dyes [91,94]. Quantum dots have been shown to be excellent turn on/off
Chemosensors 2018, 6, 8 6 of 13
chemosensors for various analytes through the attachment of analyte-sensitive molecules to the QD’s
surface. A recent turn on fluorescence sensor for NO, called Fe(III)-QD-nanoprobe, was developed with
CdSe-ZnS QDs providing the base/fluorescent portion of the sensor and tris(dithiocarbamato)iron(III)
acting as the NO responsive molecules [95]. The Fe(III)-QD-nanoprobe exhibited a dose-dependent
response to NO that was stable for over an hour and specificity to NO when compared to nitrite,
nitrate, and other reactive oxygen/nitrogen species [95]. Unfortunately, the Fe(III)-QD-nanoprobe is
irreversibly altered by exposure to NO and can therefore only be used for a single trial. Yet, since this
was the first published example of a QD sensor for NO, it is possible that further optimization will
allow the sensor to recover and be used for multiple cycles [95].
Carbon nanotubes are another class of nanoparticles that have recently been shown to act as
a biological sensor [96–98]. Carbon nanotubes are a diverse group of particles that perform differently
depending on their chirality (the angle of their carbon bonds in relation to the tube’s direction) [99,100].
Semiconducting single-wall carbon nanotubes (SWNT) are one-dimensional, pure carbon substances that
fluoresce in the near-infrared region (900–1500 nm) when excited by visible light (500–850 nm) [99,101].
The wavelength at which SWNT fluoresce (with a narrow emission spectrum) is dependent on
their chirality, and therefore, similar to QDs, multiple SWNT can be differentiated within a single
solution [101,102]. The Strano research group developed NO sensors by wrapping SWNT with specific
polymers, including 3,4-diaminophenyl-functionalized dextran or short oligonucleotide sequences such as
(AAAT)7 and (AT)15, that display a change in fluorescence intensity when exposed to NO, as depicted in
Figure 5 [103–105]. The SWNT sensors have many advantages over other fluorescence sensors including
the lack of photobleaching, ability to be detected by Raman scattering in addition to their fluorescent
signal, and emission in the near infrared range where blood and water do not absorb a large percent of
light [106–109]. A shortcoming of the current SWNT-based NO sensors is that they are turn off fluorescence
sensors, adding a layer of difficulty to the long-term detection of NO within a system [103–105].
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is conjugated to fluorescent protein variants that are then taken up by cells [110–112]. When these 
fluorescent probes were tested with HeLa cells they were shown to be taken up and expressed at 
similar rates compared to other genetically encoded probes [110]. The NO probes were shown to 
respond to NO immediately with a reversible signal, allowing for long term NO dynamics 
investigations within cells in vitro [110]. Ongoing research efforts are looking at the possibility of 
utilizing this system to develop an in vivo model [110]. One major obstacle that still prevents the 
utilization of the probes in vivo is that the fluorescence emission range that is currently being utilized 
is difficult to visualize at any depth within tissue. 
Figure 5. Schematic of a single wall carbon nanotube sensor for nitric oxide (NO) detection. The nanotube
is excited by a 561 nm laser and emits 990 nm fluorescence when there is no NO present, but when NO is
added to the system the fluorescence of the carbon nanotube is quenched [104,105].
6. enetic Biosensors
An interesting ne ay to detect O ithin a single cell is through the addition of genetic
aterials that ill code for a visual signal response in the presence of O [110]. Ronald alli and
colleagues developed a syste in hich the O responsive transcription factor of Escherichia coli (E. coli)
is conjugated to fluorescent protein variants that are then taken up by cells [110–112]. hen these
fluorescent probes were tested with HeLa cells they were shown to be taken up and expressed at similar
rates compared to other genetically encoded probes [110]. The NO probes were shown to respond to
NO immediately with a reversible signal, allowing for long term NO dynamics investigations within
cells in vitro [110]. Ongoing research efforts are looking at the possibility of utilizing this system to
develop an in vivo model [110]. One major obstacle that still prevents the utilization of the probes
in vivo is that the fluorescence emission range that is currently being utilized is difficult to visualize at
any depth within tissue.
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Table 1. Overview of the nitric oxide (NO) sensing methods discussed in this review with the assay/instruments’ molecule and rate of detection, sensitivity, scale,
strengths and current drawbacks outlined.
Detection Method Sensitivity Molecule Detected Rate of Detection Scale In Vivo, In Vitro, Both Strengths Drawbacks
Griess Assay [58–60] 1.0 µM NO2 End-Point System In Vitro
Availability, NO2 is stable and
provides an estimate of NO in
the system
Does not detect NO directly,
inconsistent results from system
to system
NOS Activity Assay [61,67] 5.0 µU L-Citrulline End-Point System In Vitro
Availability, L-citrulline is stable
and estimates NO generated
by NOS
Does not detect NO directly,
natural L-arginine sources will
interfere with readings
Electrochemical Probe [71–73] 1.0 nM NO Real-Time System Both Availability, Real-time detection,High sensitivity
Detects on a system level, cannot
detect over long time intervals
Chemiluminescent
Probes [76,77] 50 pM NO End-Point System In Vitro High sensitivity to NO
Detects on a system level, Cannot
detect in vivo
o-diamino Aromatic
Compounds [83,86,88] 5.0 µM NO Real-Time Single Cell In Vitro
Real-time detection of NO at
a cellular level
Limited aqueous solubility, false
positives with DHA and AA
Luminescent Lanthanide
Complexes [92] ~0.5 µM NO, N-Nitrosation Real-Time Single Cell Both
Real-time detection at
a cellular level Does not detect NO directly
Transition-Metal
Complexes [90,91] 4.0 µM NO Real-Time System In Vitro
Sensitivity, real-time detection
of NO Limited aqueous solubility
Quantum Dots [95] 3.3 µM NO Real-Time Single Cell Both Real-time detection of NO ata cellular level Irreversibly altered by NO
Carbon Nanotubes [103–105] 1.0 µM NO Real-Time Single Cell Both Real-time detection of NO ata cellular level Turn off sensing of NO
Genetic Biosensors [110] 50–94 nM NO Real-Time Single Cell In Vitro Real-time detection of NO ata cellular level
Fluorescence emission is not
detectable through tissue
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7. Conclusions
Nitric oxide is an essential reactive species within biological systems. As researchers are able to
understand the many complex reactions associated with NO, a deeper understanding of healthy and
diseased cells, tissues, and organisms will be uncovered. Before researchers can understand NO’s
role in biological functions there must be a way to accurately measure NO both in vitro and in vivo.
Current sensor methods, many of which are outlined in Table 1, are greatly improved over those from
just 10 or 20 years ago, and hopefully further progress can be made within the coming years.
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